You woke up, checked your phone, and the readout was positive. Phase 3 clinical trial data came back strong. Your employer stock has tripled in price in premarket trading. The equity you held in your company, which was one number yesterday, is a very different number this morning. It is now likely that it’s the largest financial asset you have ever owned.
You are not in a bad situation. But, you are in a situation that requires a specific kind of clear thinking — and this exact moment makes that thinking very hard to access. Your instinct right now is that the obvious move is to hold. That instinct is exactly where clear thinking tends to break down.
What should I do with my biotech stock after a positive clinical trial result triples the stock price?
Separate two things that feel like one — deciding on a plan for your stock, and executing that plan — because the size of the decision just scaled overnight, while the conditions for making it well are among the most difficult they will ever be.
The worst possible moment to make the biggest financial decision you have ever faced
Here is what changed overnight. The stock tripled, so the decision about what to do with it just tripled in size too. What was a meaningful fraction of your net worth yesterday may now be worth more than your home. The stakes scaled instantly.
And when decisions become much larger, they don’t often become easier to make. Instead, larger decisions tend to result in greater complexity, while emotions are naturally running high. The stock is still moving. And your trading window may be about to close, or may already be closed. That is a lot of pressure applied to the biggest financial decision of your life, all at once.
The way through is to separate making your decision from taking action. Deciding what you want to do is one thing. Doing it is another. The best time to decide is in advance — ideally before a readout, when you can ask yourself how you would respond to a stock that tripled. How much would you sell? Over what period of time?
If you settled those questions in advance, there is nothing left to decide this morning. There is only execution. And that matters, because the time between a positive readout and the next opportunity to trade your stock can be short. A plan settled ahead of time turns your limited decision time into execution time. That is how cooler heads prevail when you have a very limited amount of time to make a very big decision.
Why holding feels obvious after a readout that validated everything
The motivation to wait after a positive readout is powerful, and it is specific to biotech in a way that other windfalls are not.
The data validated years of work. It confirmed the scientific judgment that drew most people to work for the company in the first place. You believed in the science, the science just proved you right, and now there is a compelling story of continued upside. Holding through FDA approval feels like the natural next chapter. Why sell now, right before the payoff?
Here is what that reasoning misses. A stock that tripled on Phase 3 data is not sitting at a number that ignores approval. The market already moved. That new, tripled price already reflects a significant probability that the drug gets approved. You are not holding a lottery ticket that hasn't been priced yet — you are holding one that is currently priced as if approval has already occurred.
From here, the next major move can go either way. Approval, delay, a surprising label restriction, a competitor's data — the outcome is still binary, and you are now holding a position that already banked upon optimism. That does not mean selling is right for you. It means the case for revisiting how much of your net worth sits in one stock is strongest at exactly the moment the urge to hold is strongest. Both can be true at once.
The tax lots hiding inside a position that tripled overnight
Before you can act clearly, you need to know what you actually hold — and it is more complicated than a single number on a brokerage screen.
Your position almost certainly came from shares acquired at different times. Some shares came from exercising stock options you received before your company went public, while others may come from RSUs granted after the IPO. Each of these is a separate tax lot, with its own cost basis and holding period — so the tax treatment of a sale can differ meaningfully depending on which shares you sell.
Why does that matter? Because each position carries its own cost basis — what you effectively paid for those shares — and its own holding period — how long you have owned them. Both drive how a sale gets taxed. Shares held longer than a year are taxed at lower long-term capital gains rates. Shares held less than a year are taxed at higher ordinary income rates. That’s why two lots that look identical in your account can produce very different tax bills when sold.
So if you decide to reduce the position, which specific shares you sell is a real decision, not a detail. Selling the lot that fits your situation requires knowing what you hold before the trade is placed. This is the kind of thing that seems minor in the moment and turns out to matter a great deal at tax time — not because anyone was careless, but because the rules reward knowing the picture in advance.
Confirm the window, settle the plan, then act
Walking into this morning without a plan is walking into the biggest decision of your financial life blind, under pressure, with the clock running. That is not a character flaw. It is just the situation that frequently results from the release of clinical trial data.
Two things deserve answers before the market opens. First, is your trading window actually open. Second, if you were going to reduce this position, what would the plan be — how much, on what schedule, and from which tax lots. The first has a discrete answer. The second has a much better answer if you built it before today.
Pro-Tip: Before the trading window opens following a positive readout, two questions have useful answers: is my trading window currently open, and if this position has suddenly appreciated in price, what is my plan for it?
If you'd like to explore whether ongoing financial planning and investment management make sense for your situation, you can schedule an intro call here:
Common Questions
Can I sell my biotech company stock after a positive Phase 3 trial readout?
That depends on whether your trading window is open. Most public-company employees can only trade during defined periods, and a major readout can affect whether the window is open or closed. Your compliance team is the only source that can confirm your current status with certainty — and that confirmation should come before you plan any trade, not after.
How are gains taxed on biotech stock that triples after a clinical trial result?
It depends on the individual lots you sell. Each batch of shares has its own cost basis and holding period. Shares held longer than a year are taxed at lower long-term capital gains rates, while shares held less than a year are taxed at higher ordinary income rates similar to your salary. Because your stock arrived in your account at various points in time and at different prices, the tax outcome of a sale can vary widely depending on which shares you sell.
How do I manage a large biotech stock position after a major positive catalyst?
Start by separating the decision from taking action. Decide, ideally in a calmer moment, how much stock you are comfortable holding and over what period you might intend to sell it. This should occur before data goes public, with a plan for what you would do if things turn out well (or, also if they aren’t as good as you might be hoping for). Then confirm your trading window status and understand what you own before placing any trade. The moment itself makes clear thinking hard, which is why a plan built in advance tends to produce far better outcomes than one improvised in the moment.
This blog was written by Jeremy Bohne, Principal & Founder of Paceline Wealth Management. Paceline is a fee-only investment advisor serving clients in the Boston area, and on a remote basis throughout the country. Paceline specializes in helping tech and biotech leaders, business owners, physicians, and those seeking financial planning services.